Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies

Breast

Volumn 17, Issue 5, 2008, Pages 499-505

  Fabi, Alessandra ^a   Metro, Giulio ^a   Ferretti, Gianluigi ^a   Giannarelli, Diana ^a   Di Cosimo, Serena ^a   Papaldo, Paola ^a   Mottolese, Marcella ^a   Carlini, Paolo ^a   Felici, Alessandra ^a   Russillo, Michelangelo ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Disease progression; HER 2; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SYSTEMATIC REVIEW;

EID: 53149153173     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.03.006     Document Type: Article

References (29)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
2. Seshadri R., Firgaira F.A., Horsfall D.J., McCaul K., Setlur V., and Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11 (1993) 1936-1942 The South Australian Breast Cancer Study Group
3. Ross J.S., and Fletcher J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16 (1998) 413-428
4. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scoll S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
5. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
6. Esteva F.J., Valero V., Booser D., Guerra L.T., Murray J.L., Pusztai L., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 1800-1808
7. Burstein H.J., Harris L.N., Marcom P.K., Lambert-Falls R., Havlin K., Overmoyer B., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21 (2003) 2889-2895
8. Pegram M.D., Konecny G.E., O'Callaghan C., Beryt M., Pietras R., and Slamon D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96 (2004) 739-749
9. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 (2005) 4265-4274
10. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
11. Demonty G., Bernard-Marty C., Puglisi F., Mancini I., and Piccart M. Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer 43 (2007) 497-509
12. Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., and Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17 (1998) 2235-2249
13. Yeon C.H., Slamon D., Patel R., Cartmell A., Leyland-Jones B., Klein P., et al. Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT). Proc Am Soc Clin Oncol 22 (2004) 680 [abstract]
14. Tripathy D., Slamon D.J., Cobleigh M., Arnold A., Saleh M., Mortimer J.E., et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22 (2004) 1063-1070
15. Fujimoto-Ouchi K., Sekiguchi F., and Mori K. Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Proc Am Assoc Cancer Res 46 (2005) 5062 [abstract]
16. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
17. Chung K.C., Burns P.B., and Myra Kim H. A practical guide to meta-analysis. J Hand Surg 31 (2006) 1671-1678
18. Christodoulou C., Klouvas G., Pateli A., Mellou S., Sgouros J., and Skarlos D.V. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer. Anticancer Res 23 (2003) 737-744
19. Stemmler H.J., Kahlert S., Siekiera W., Untch M., Heinrich B., and Heinemann V. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 28 (2005) 582-586
20. Fountzilas G., Razis E., Tsavdaridis D., Calogera-Fountzila A., Aravantinos G., Razis E., et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 4 (2003) 120-125
21. Gelmon K.A., Mackey J., Verma S., Gertler S.Z., Bangemann N., Klimo P., et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5 (2004) 52-58
22. Garcia-Saenz J.A., Martin M., Puente J., Lopez-Tarruella S., Casado A., Moreno F., et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 6 (2005) 325-329
23. Bartsch R., Wenzel C., Hussian D., Pluschnig U., Sevelda U., Koestler W., et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 6 (2006) 63-68
24. Montemurro F., Donadio M., Clavarezza M., Redana S., Jacomuzzi M.E., Valabrega G., et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11 (2006) 318-324
25. Pusztai L., and Esteva F.J. Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest 24 (2006) 187-191
26. Jones S.E., Erban J., Overmoyer B., Budd G.T., Hutchins L., Lower E., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23 (2005) 5542-5551
27. O'Shaughnessy J., Miles D., Vukelja S., Moiseyenko V., Ayoub J.P., Cervantes G., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (2002) 2812-2823
28. Extra J.M., Antoine E.C., Vincent-Salomon A., Bergougnoux L., Campana F., and Namer M. Favourable effect of continued trastuzumab treatment in metastastic breast cancer patients: results from the French hermine cohort study. San Antonio Breast Cancer Symposium 100 (2006) 2064 [abstract]
29. Geyer C.E., Forster J., Lindquist D., Chan S., Romien C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 28 (2006) 2733-2743